Development of therapies for treatment and prevention of COVID-19

Learning objectives: Describe the therapeutic agents in evaluation for the treatment of COVID-19 infection.

Describe the difference in the vaccine platforms in development with the intent of prevention infections with SARS-CoV-2.


Disease X”: 6 Months Into the COVID-19 Pandemic

Learning objectives: Learn the threat posed by single-stranded RNA viruses with respect to emergence of pathogens causing pandemics, including COVID-19

Learn the pathophysiology and clinical manifestations of COVID-19 infection.

Session date: 
09/29/2020 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Kathleen M. Mullane, DO, Pharm. D., FIDSA and David L. Pitrak, MD, FIDSA